Purpose: To evaluate the outcomes of the patients who were infected with colistin-only-
susceptible (COS) Acinetobacter baumannii and treated with either colistin monotherapy or …

Background: Acinetobacter baumannii (AB) is increasingly becoming a clinically relevant
organism due to the rising number of associated nosocomial infections. The therapeutic …

Emerging resistance to colistin in Acinetobacter baumannii clinical strains is concerning
because of the limited therapeutic choices for these important clinical pathogens. We …

Background We evaluated the association between mortality and colistin resistance in
Acinetobacter baumannii infections and the interaction with antibiotic therapy. Methods This …

Objectives The increased incidence of nosocomial infections by multidrug-resistant
organisms has motivated the re-introduction of colistin in combination with other …

Polymyxins are one of the last-line antibiotics for multidrug-resistant Acinetobacter
baumannii. Reports have demonstrated the emergence of colistin heteroresistance in A …

Objectives The aim of this study was to confirm the synergistic effect of colistin/rifampicin
combination therapy compared with colistin monotherapy in pneumonia caused by colistin …

Multidrug resistant among Acinetobacter baumannii infection is associated with a high
mortality rate and limits the therapeutic options. The aim of this study was to assess the …

Purpose Colistin is a drug of last resort for treating multidrug-resistant Acinetobacter
baumannii infections. Unfortunately, colistin-resistant A. baumannii (CoR-AB) has been …

Emerging resistance to colistin in clinical Acinetobacter baumannii isolates is of growing
concern. Since current treatment options for these strains are extremely limited, we …